Reinitiation of GLP-1 common after discontinuation

CHICAGO — Among patients with type 2 diabetes who discontinued use of a GLP-1 receptor agonist, more than half reinitiated within 1 year and about two-thirds reinitiated within 2 years, researchers reported at ENDO 2026. “The question we were asking is, of the patients who do go on GLP-1s, who have type 2 diabetes, how many of them actually stay on treatment?” Sanjeev Rampam, MD, resident